Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl

Date : 11/08/2019 @ 6:30PM
Source : Dow Jones News
Stock : Celgene Corporation (CELG)
Quote : 108.24  0.0 (0.00%) @ 1:00AM

Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl

Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart

6 Months : From Oct 2019 to Apr 2020

Click Here for more Acceleron Pharma Charts.
   By Stephen Nakrosis 

Shares of Acceleron Pharma Inc. (XLRN) are moving higher in Friday's market, following the U.S. Food and Drug Administration's announcement it had approved Reblozyl for the treatment of anemia patients with beta thalassemia who require regular red blood cell transfusions.

Celgene Corp. (CELG) and Acceleron are jointly developing Reblozyl, the companies said.

At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade at $43.05.

Celgene shares were up 0.35%, to $109.38, following the news.


Write to Stephen Nakrosis at


(END) Dow Jones Newswires

November 08, 2019 13:15 ET (18:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.